



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Darrell R. Anderson, et al.

Group Art Unit: 1644

Application No. 09/758,173

Filed: January 12, 2001

Title: HUMAN B7.1 SPECIFIC PRIMATIZED ANTIBODIES AND TRANSFECTOMAS
EXPRESSING SAID ANTIBODIES

* * * * *

ELECTION REPLY AND AMENDMENT

Hon. Commissioner of Patents
Washington, D.C. 20231

RECEIVED
APR 15 2002
TECH CENTER 1600/2900

Sir:

In response to the Office Action (Restriction) mailed on March 12, 2002, Applicants elect without traverse species A, i.e., the administration of an anti-B7.1 antibody.

Also, Applicants introduce the following additional claims directed to the elected invention.

Sub D3
--32. The method of claim 21 wherein the antibody is a primatized antibody having the variable regions of the 16C10 antibody wherein said antibody has the variable sequences contained in Figures 8a-8b, 9a-9b and 10a-10b.

33. The method of claim 21 wherein the anti-B7 antibody is a monoclonal antibody that specifically binds human B7.1, having a human gamma 4 constant domain.

B2
34. The method of claim 33 wherein said constant domain contains a mutation in the CH2 region that eliminates FcR binding and a mutation in the hinge region that enhances the stability of the heavy chain disulfide bound interaction.

35. The method of claim 32 wherein said antibody is administered at a dosage ranging from 0.05 to 100 mg/kg/day.

36. The method of claim 32 where said antibody is administered at a dosage ranging from 0.5 to 100 mg/kg/day.--


Also, amend claim 30 as set forth below.

B1 30. (Amended) The method of claim 29 wherein parenterally includes intravenous, intraperitoneal, intramuscular, and subcutaneous administration.

It is believed that this is a complete response to the outstanding Restriction Requirement.

Respectfully submitted,
Pillsbury Winthrop LLP

Date: April 12, 2002

By: 
Robin L. Teskin
Registration No. 35,030

1600 Tysons Boulevard
McLean, VA 22102
(703) 905-2200 Telephone
(703) 905-2500 Facsimile

APPENDIX

30. (Amended) The method of claim 29 wherein parenterally includes intravenous, intraperitoneal, intramuscular, and subcutaneous ~~and rectal~~ administration .